Pacific Biosciences of California reported fourth‑quarter 2025 results that surpassed analyst expectations, with revenue of $44.6 million to $44.65 million and a non‑GAAP loss per share of $‑0.12. The company beat consensus estimates of $‑0.13 to $‑0.16, delivering an EPS beat of $0.01 to $0.04 per share. Revenue growth of 14% year‑over‑year and 16% sequentially reflected strong demand across the company’s product portfolio.
The revenue lift was driven primarily by consumables, which reached a record $21.6 million, up 15% from the prior year, and by instrument sales, which grew 13% to $17.3 million. The higher mix of consumables, which carry higher margins, and increased Vega shipments contributed to the top‑line expansion, while the company noted continued growth in its clinical market segment that helped offset pressure in the academic funding environment.
Gross margin improved markedly, with non‑GAAP gross margin rising to 40% from 31% in Q4 2024. The improvement is attributed to a higher consumables mix, cost‑reduction initiatives for Revio and Vega systems, and higher yields for Revio SMRT Cells. The margin expansion signals that PacBio’s operational leverage is improving as the company scales its long‑read platforms.
For the full year 2026, PacBio guided revenue of $165 million to $180 million, a midpoint of roughly $172 million, representing about 8% growth from the prior year. The company also expects a gross‑margin improvement of 100 to 400 basis points. The guidance reflects confidence in sustained demand for its long‑read sequencing solutions and the anticipated impact of upcoming product launches such as SPRQ‑Nx and SparkNex chemistry.
CEO Christian Henry highlighted the company’s strategic focus, noting that the sale of short‑read assets has strengthened the balance sheet and positioned PacBio to drive adoption of its long‑read platforms. He added that the record consumables revenue and growth in the clinical market underscore the company’s ability to capture new customer segments while the launch of SPRQ‑Nx is expected to lower sequencing costs and expand market share.
Market reaction to the earnings was muted. After the announcement, the stock rose only 1.63% in aftermarket trading, and subsequent sessions showed little movement. Investors cited the modest revenue guidance, ongoing academic funding headwinds, and the company’s underperformance relative to the S&P 500 as reasons for the restrained response.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.